Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Meeting
CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a medical-phase biotechnology…
CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a medical-phase biotechnology enterprise revolutionary the first systematic strategy to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ system, currently introduced that Thomas McCauley, Main Scientific Officer, will take part in a hearth chat at the 2022 Wedbush PacGrow Health care Conference on August 10, 2022, at 8 a.m. ET.
A reside webcast of the fireside chat will be offered on the Traders & Media portion of the Company’s website at www.omegatherapeutics.com. An archived replay of the hearth chat will be accessible on the similar internet site for around 90 days.
About Omega Therapeutics
Omega Therapeutics, founded by Flagship Revolutionary, is a medical-phase biotechnology corporation revolutionary the initially systematic approach to use mRNA therapeutics as a new course of programmable epigenetic medications. The company’s OMEGA Epigenomic Programming™ platform harnesses the electrical power of epigenetics, the mechanism that controls gene expression and each factor of an organism’s daily life from mobile genesis, development, and differentiation to mobile dying. Utilizing a suite of technologies, paired with Omega’s process of systematic, rational, and integrative drug design and style, the OMEGA system enables command of basic epigenetic procedures to right the root result in of disease by returning aberrant gene expression to a usual variety without altering indigenous nucleic acid sequences. Omega’s modular and programmable mRNA medications, Omega Epigenomic Controllers™, goal particular epigenomic loci within insulated genomic domains, EpiZips™, from among countless numbers of exclusive, mapped, and validated genome-huge DNA-sequences, with substantial specificity to durably tune single or various genes to treat and treatment health conditions via Precision Genomic Control™. Omega is now advancing a wide pipeline of enhancement candidates spanning a variety of illness places, like oncology, regenerative drugs, multigenic ailments which include immunology, and decide on monogenic ailments, like alopecia.
For extra info, visit omegatherapeutics.com, or comply with us on Twitter and LinkedIn.
Contacts
Media speak to:
Jason Braco
LifeSci Communications
646.751.4361
[email protected]
Trader make contact with:
Kevin Murphy
Argot Associates
212.600.1902
[email protected]
Resource Omega Therapeutics
